SHANGHAI, June 6 (Reuters) - At least 11 generic versions of Novo Nordisk's popular diabetes drug Ozempic are in the final stages of clinical trials in China, as developers seek to profit from an early patent expiry of the therapy's active ingredient semaglutide in China.

COMPANIES WHICH COMPLETED PHASE 3

Hangzhou Jiuyuan Gene Engineering: It has said its drug has "similar clinical efficacy and safety" as Ozempic

Livzon Pharmaceutical Group

COMPANIES THAT FINISHED RECRUITING FOR PHASE 3 TRIALS

Chongqing Chenan Biopharmaceutical/Shanghai Bovax Biotechnology

COMPANIES RECRUITING PARTICIPANTS FOR PHASE 3 TRIALS

CSPC Pharmaceutical Group

Huadong Medicine/Peg-Bio Biopharm

Sino Biopharmaceutical Limited subsidiary

Qilu Pharmaceutical

COMPANIES THAT HAVE YET TO START RECRUITING

Brilliant Pharmaceuticals

QL Biopharm

Sihuan Pharmaceutical subsidiary

United Laboratories

Source: records from http://www.chinadrugtrials.org.cn/ (Reporting by Andrew Silver; Editing by Muralikumar Anantharaman)